These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25871827)

  • 1. Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine.
    Riede O; Seifert K; Oswald D; Endmann A; Hock C; Winkler A; Salguero FJ; Schroff M; Croft SL; Juhls C
    Gene Ther; 2015 Aug; 22(8):628-35. PubMed ID: 25871827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis.
    Das S; Freier A; Boussoffara T; Das S; Oswald D; Losch FO; Selka M; Sacerdoti-Sierra N; Schönian G; Wiesmüller KH; Seifert K; Schroff M; Juhls C; Jaffe CL; Roy S; Das P; Louzir H; Croft SL; Modabber F; Walden P
    Sci Transl Med; 2014 Apr; 6(234):234ra56. PubMed ID: 24786324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.
    Ahmed SB; Touihri L; Chtourou Y; Dellagi K; Bahloul C
    Vaccine; 2009 Jan; 27(1):99-106. PubMed ID: 18951941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
    East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate.
    Seifert K; Juhls C; Salguero FJ; Croft SL
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5819-23. PubMed ID: 26055371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation.
    Dolter KE; Evans CF; Ellefsen B; Song J; Boente-Carrera M; Vittorino R; Rosenberg TJ; Hannaman D; Vasan S
    Vaccine; 2011 Jan; 29(4):795-803. PubMed ID: 21094270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leishmania transmission-blocking vaccines: a review.
    Tonui WK
    East Afr Med J; 1999 Feb; 76(2):93-6. PubMed ID: 10442130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial preclinical safety of non-replicating human endogenous retrovirus envelope protein-coated baculovirus vector-based vaccines against human papillomavirus.
    Han SE; Kim MG; Lee S; Cho HJ; Byun Y; Kim S; Kim YB; Choi Y; Oh YK
    J Appl Toxicol; 2013 Dec; 33(12):1474-83. PubMed ID: 22987290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine candidates for leishmaniasis: a review.
    Nagill R; Kaur S
    Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
    Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
    Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunology of Leishmania infection and the implications for vaccine development.
    Vanloubbeeck Y; Jones DE
    Ann N Y Acad Sci; 2004 Oct; 1026():267-72. PubMed ID: 15604504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of MIDGE-Th1 DNA vaccines with the cationic lipid SAINT-18: studies on formulation, biodistribution and vector clearance.
    Endmann A; Oswald D; Riede O; Talman EG; Vos RE; Schroff M; Kleuss C; Ruiters MH; Juhls C
    Vaccine; 2014 Jun; 32(27):3460-7. PubMed ID: 24681271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leishmania genome analysis and high-throughput immunological screening identifies tuzin as a novel vaccine candidate against visceral leishmaniasis.
    Lakshmi BS; Wang R; Madhubala R
    Vaccine; 2014 Jun; 32(30):3816-22. PubMed ID: 24814525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis.
    de Jesus Pereira NC; Régis WC; Costa LE; de Oliveira JS; da Silva AG; Martins VT; Duarte MC; de Souza JR; Lage PS; Schneider MS; Melo MN; Soto M; Soares SA; Tavares CA; Chávez-Fumagalli MA; Coelho EA
    Exp Parasitol; 2015 Jun; 153():180-90. PubMed ID: 25845753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery.
    Plog MS; Guyre CA; Roberts BL; Goldberg M; St George JA; Perricone MA
    Hum Gene Ther; 2006 Jul; 17(7):705-16. PubMed ID: 16839270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice.
    Hanke T; McMichael AJ; Dennis MJ; Sharpe SA; Powell LA; McLoughlin L; Crome SJ
    Vaccine; 2005 Feb; 23(12):1507-14. PubMed ID: 15670887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phage-fused epitopes from Leishmania infantum used as immunogenic vaccines confer partial protection against Leishmania amazonensis infection.
    Costa LE; Chávez-Fumagalli MA; Martins VT; Duarte MC; Lage DP; Lima MI; Pereira NC; Soto M; Tavares CA; Goulart LR; Coelho EA
    Parasitology; 2015 Sep; 142(10):1335-47. PubMed ID: 26099574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.